Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
AstraZeneca
>
INSIGHT
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="anonymous, post: 6255385"]Let me preface this by saying I have been around a long time and have seen my share of questionable number reports. This is regarding Symbicort. How can Matrix for the last week see a bounce for BoB from the previous week, yet the QTD performance dropped almost 2% based on Insight from what was shown on the previous report? </p><p><br /></p><p>Only way this makes any sense is that the numbers were recalibrated in previous weeks to drop the performance as much as it did. There should be no way % to plan this far into a qtr would drop this much unless the floor dropped out in the last week (which it didn’t), or.....manipulation of the data. </p><p><br /></p><p>They will lie and say ridiculous crap about monthly vs. weekly and cleaning up the docs that are blocked, but we have all come to realize that is horse manure since in the grand scheme, those numbers are small. Obviously, bonus must still be over the budget set for 2019 and as a result people will be held accountable to false numbers.[/QUOTE]</p><p><br /></p>
[QUOTE="anonymous, post: 6255385"]Let me preface this by saying I have been around a long time and have seen my share of questionable number reports. This is regarding Symbicort. How can Matrix for the last week see a bounce for BoB from the previous week, yet the QTD performance dropped almost 2% based on Insight from what was shown on the previous report? Only way this makes any sense is that the numbers were recalibrated in previous weeks to drop the performance as much as it did. There should be no way % to plan this far into a qtr would drop this much unless the floor dropped out in the last week (which it didn’t), or.....manipulation of the data. They will lie and say ridiculous crap about monthly vs. weekly and cleaning up the docs that are blocked, but we have all come to realize that is horse manure since in the grand scheme, those numbers are small. Obviously, bonus must still be over the budget set for 2019 and as a result people will be held accountable to false numbers.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
AstraZeneca
>
INSIGHT
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
AstraZeneca
>
INSIGHT
>